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A B S T R A C T
Purpose: Mitochondrial disorders (MIDs) frequently manifest phenotypically as epilepsy (mitochondrial
epilepsy). Mitochondrial epilepsy occurs in early-onset as well as late-onset syndromic and non-
syndromic MIDs. We were interested in the types of epilepsy, the prevalence of mitochondrial epilepsy,
the type and effectiveness of treatment, and in the outcome of adult MID patients with epilepsy.
Methods: We retrospectively evaluated adult patients with syndromic or non-syndromic MIDs and
epilepsy. MIDs were classiﬁed according to the modiﬁed Walker criteria as deﬁnite, probable, and
possible.
Results: Epilepsy in adult patients with a MID was classiﬁed as ‘‘structural/metabolic’’ in two-thirds of
the cases and as ‘‘genetic’’ in one-third of the cases. Although all types of seizures may occur in
mitochondrial epilepsy, adult patients most frequently presented with generalised tonic–clonic seizures,
partial seizures, convulsive status epilepticus, or non-convulsive status epilepticus. Cerebral imaging
was normal in one-third of the patients. Two-thirds of the adult patients with mitochondrial epilepsy
who took antiepileptic drugs received monotherapy, one-third combination treatment. The antiepileptic
drugs most frequently administered included levetiracetam, lamotrigine, valproic acid, and gabapentin.
Antiepileptic drugs were usually well tolerated and the outcome favourable.
Conclusions: Adult mitochondrial epilepsy appears to be less frequent than previously believed but the
prevalence strongly depends on patient selection. Mitochondrial epilepsy is most frequently ‘‘structural/
metabolic’’. AEDs recommended for mitochondrial epilepsy include levetiracetam, lamotrigine,
gabapentin and lacosamide. The outcome of mitochondrial epilepsy may be more favourable if
mitochondrion-toxic AEDs are avoided. Only if non-mitochondrion-toxic AEDs are ineffective,
mitochondrion-toxic AEDs may be used.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Epilepsy is a frequent phenotypic manifestation of syndromic as
well as non-syndromic mitochondrial disorders (MIDs).1 According
to the new classiﬁcation of epilepsies, epilepsy in MIDs may have a
genetic or structural/metabolic cause in case of a previous cerebral
lesion or dysfunction, or may be of unknown aetiology in case of an
undetermined cause.2 Structural/metabolic epilepsy in MIDs may be
due to atherothrombotic or embolic ischaemic stroke, a stroke-like
lesion, atrophy, white matter lesions, grey matter lesions, cerebro-
spinal ﬂuid (CSF)-lactacidosis, cardiac involvement in the MID,
endocrinopathy, or due to other disorders, which may cause
structural central nervous system (CNS) disease.3 Epilepsy may be
a collateral manifestation of a MID or the dominant feature of the
phenotype, such as in mitochondrial encephalopathy, lactacidosis
and stroke-like episodes (MELAS)-syndrome, myoclonic epilepsy
with ragged-red ﬁbres (MERRF)-syndrome, Leigh-syndrome, myo-
clonic epilepsy, myopathy and sensory ataxia (MEMSA)-syndrome,
also known as spino-cerebellar ataxia with epilepsy (SCAE),vier Ltd. All rights reserved.
Table 2
Unexplained instrumental ﬁndings other than a muscle biopsy or genetic testing
indicative of a MID.1
Cerebral imaging
Basal ganglia calciﬁcation, focal cerebral atrophy, white matter lesions,
stroke-like lesion, optic atrophy, pituitary adenoma, empty sella
PNS
Polyneuropathy, motor neuron disease, myopathy
Eyes
Pigmentary retinopathy, cataract, glaucoma, prolonged visually evoked
potentials
Ears
Hypoacusis on audiometry
Serum/CSF tests
Elevated serum/CSF lactate, elevated CSF protein, pleocytosis, recurrent CK-
elevation, elevated liver function parameters, elevated amylase, renal
insufﬁciency, hyperlipidemia, hyperuricemia
Blood cells
Anaemia, thrombopenia, thrombocytosis, leucopenia, eosinophilia
Heart
Hypertrophic cardiomyopathy, dilative cardiomyopathy, left ventricular
hypertrabeculation (noncompaction), Takotsubo syndrome, arrhythmias
Kidneys
Kidney cysts, nephrolithiasis, renal failure
Guts
Parotitis, hepatopathy, liver cysts, pancreatitis, pancreatic cysts.
diverticulosis, ‘‘nonspeciﬁc’’ colitis
Endocrinium
Osteoporosis, hypopituitarism, hypocorticism, diabetes, hypoaldosteronism,
hypothyroidism, hyperthyroidism, hypogonadism
Vessels
Atherosclerosis, arterial stenosis, occlusion, aneurysm, ectasia, dissection, or
rupture
Skin
Madarosis, psoriasis, lipomatosis
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with neuropathy, dysarthria and ophthalmoparesis (SANDO)-
syndrome, or Alpers–Huttenlocher-syndrome (AHS).3 Little is
known about the predominant types and frequency of seizures,
treatment and outcome of epilepsy in adult patients with a MID. The
present study was therefore designed to describe: (1) which types of
epilepsy occur in adult MIDs, (2) what the prevalence of deﬁnite,
probable or possible mitochondrial epilepsy is in adults, (3) what the
most effective treatment is, and (4) what outcome can be most likely
expected in these patient groups.
2. Patients and methods
Retrospectively evaluated were patients with syndromic or
non-syndromic MIDs and epilepsy, who attended in- or outpatient
units of the Krankenanstalt Rudolfstiftung. MIDs were classiﬁed
according to the modiﬁed Walker criteria as deﬁnite, probable, and
possible.4 A MID was classiﬁed as ‘‘deﬁnite’’ if the clinical
presentation was indicative of a MID and if there was biochemical
(deﬁciency of complex I, II, or IV of the respiratory chain) or genetic
evidence of a mitochondrial defect. A MID was classiﬁed as
‘‘probable’’ if the clinical presentation was indicative of a MID and
if immuno-histological investigations on muscle biopsy showed
COX-negative ﬁbres, ragged-red-ﬁbres, SDH-hyper-reactive ﬁbres,
or abnormally shaped or structured mitochondria with or without
paracristalline inclusions or glycogen or fat depositions on electron
microscopy.4 A MID was classiﬁed as ‘‘possible’’ if the clinical
presentation suggested a MID (Table 1) and if instrumental
investigations other than a muscle biopsy were indicative of a MID
(Table 2).4 The clinical presentation was considered ‘‘suggestive’’ of
a MID if at least 3 of the clinical ﬁndings listed in Table 1 were
present and if additionally at least 3 instrumental investigations
listed in Table 2 were present or if <3 clinical abnormalities and
>10 abnormalities on instrumental investigations were found in a
single patient.
Included were all patients in whom seizures had occurred
previously without requiring antiepileptic drug (AED) treatment at
the time of the consultation and those who were taking AED
treatment at the time of attendance or had experienced seizures
during the last year prior to the consultation. Epilepsy was
classiﬁed according to its aetiology following the classiﬁcation ofTable 1
History, symptoms and signs suggestive of a MID.1
PNS
Double vision, ptosis, ophthalmoparesis, dropped head, camptocormia,
cervical spine syndrome, limb weakness, muscular respiratory insufﬁciency,
exercise intolerance, fatigue, easy fatigability, sore muscles, myalgia, muscle
cramps, sensory disturbances, sensory ataxia, muscle rupture
CNS
Disorientation, confusion, autism, psychosis, lethargy, cognitive decline,
dementia, seizures, stroke-like episode, ischaemic stroke, hypersomnia,
migraine, migraine-like headache, cluster headache, cerebellar ataxia,
movement disorder, transverse syndrome
Eyes
Visual impairment, blurred vision, visual ﬁeld defects, painful bulbs
Ear
Hypoacusis, acute hearing loss, tinnitus
Endocrine organs
Short stature, sicca-syndrome, hyperhidrosis, impotence, hypogonadism,
adynamia
Heart
Palpitations, orthopnoe, exertional dyspnoea, leg oedema, neck vein
distension, recurrent syncopes, sudden cardiac death
Gastrointestinal
Dysphagia, vomiting, diarrhoea, obstipation, jaundice, colics, pancreatitis
Kidneys
Colics from nephrolithiasis
Skeleton
Scoliosis, arthralgia, dysmorphismthe International League against Epilepsy (ILAE) 20102 as genetic
or presumed genetic, as structural or metabolic, or unknown.
Seizure types were classiﬁed as generalised or focal.2 Epilepsy in
MIDs with stroke-like episodes was classiﬁed as genetic but not as
structural/metabolic since the stroke-like lesion was not regarded
as prerequisite for the development of seizures.
3. Results
Altogether, 444 patients were classiﬁed as MID during the
observation period of 4 years, 15 as deﬁnite, 54 as probable and
375 as possible MID (Table 3). Insufﬁcient or inconclusive data
concerning epilepsy were available in 3 patients (Table 3). Among
the remaining 441 patients, epilepsy was associated with a MID in
60 patients: in 3 cases MID was categorised as deﬁnite, in 12 as
probable, and in 45 as possible (Table 3). Among the 3 patients with
deﬁnite MID and epilepsy one presented with syndromic MID
(MELAS-syndrome (respiratory chain complex defect, >2% ragged-
red ﬁbres, >2% COX-negative ﬁbres)) and two with non-syndromic
MIDs. One of the patients with deﬁnite non-syndromic MID had a
multisystem disease with multiple respiratory chain complex
deﬁciencies and the second patient epilepsy and cardiomyopathy
with complex-I defect, >2% ragged-red ﬁbres, >2% COX-negative
ﬁbres, and para-cristalline inclusions on electron microscopy. The
number of abnormalities listed in Tables 1 and 2 found in the 45
possible MIDs are presented in Table 4.
Among the 60 patients with epilepsy 38 were female and 22
male. Mean age was 67.2 years (range: 35–90 years). None of the
patients with probable MIDs and epilepsy ﬁtted into a distinct
mitochondrial syndrome. Epilepsy had a structural/metabolic
aetiology in 39 cases. It was attributed to previous ischaemic
stroke in 14 patients, to chronic alcohol consumption in 8, to
cerebral atrophy in 7, to a cerebral tumour in 3, to a head trauma,
encephalitis, or hypoxia each in 2, and to superﬁcial siderosis in 1
(Fig. 2). In 21 patients, epilepsy was classiﬁed as genetic,
Table 3
Results of the present investigation.
Total Deﬁnite Probable Possible
NP screened 444 15 54 375
NP insufﬁcient data 3 1 0 2
NP with epilepsy 60 (14%) 3 (20%) 12 (22%) 45
(12%)
NP with genetic epilepsy 21 3 6 12
NP with structural epilepsy 39 0 6 33
Stroke 14 0 2 12
Alcoholism 8 0 2 6
Cerebral atrophy 7 0 0 7
Tumour 3 0 0 3
Encephalitis 2 0 1 1
Hypoxia 2 0 0 2
Trauma 2 0 0 2
Superﬁcial siderosis 1 0 0 1
NP with focal seizures 6 0 0 6
NP with generalised seizures 51 2 12 37
NP with focal + generalised seizures 2 1 0 1
Seizure type unknown 1 0 0 1
NP receiving treatment 48 3 9 36
LEV 12 0 2 10
LEV, OXC 2 0 0 2
LEV, LTG, LAC 2 1 0 1
LEV, LTG, OXC 1 0 0 1
LTG 13 0 4 9
LTG, LAC 1 1 0 0
LTG, GBP 1 0 0 1
VPA 1 0 1 0
VPA, LEV 3 0 0 3
VPA, LTG 1 0 0 1
VPA, GBP 1 0 0 1
VPA, TPM 1 0 0 1
VPA, LEV, LTG 1 0 0 1
CBZ 2 0 0 2
CBZ, PRM 1 0 0 1
GBP 4 1 2 1
OXC 1 0 0 1
NP without AED treatment 11 0 3 8
Unknown if on an AED 1 0 0 1
NP, number of patients.
Fig. 1. Number of patients with deﬁnite, probable, and possible MID who presented
with genetic or structural/metabolic epilepsy.
J. Finsterer, S.Z. Mahjoub / Seizure 22 (2013) 119–123 121attributable to the proven or presumed genetic defect responsible
for the MID, presumably manifesting also in the brain. Among all
patients with epilepsy and MID, seizures were generalised in 51
patients, focal in 6 patients, and generalised and focal in 2 patients
(Table 3 and Fig. 1). The history was positive for a non-convulsive
status epilepticus in three patients and for a convulsive status
epilepticus in two patients. Sudden unexplained death in epilepsy
(SUDEP) had not occurred in any of the patients.
At the time of the last consultation, 48 patients took AEDs and
11 did not. Reasons for not taking AEDs were general aversion
against AEDs, unauthorised discontinuation of AEDs, or previous
epilepsy, which no longer required AED treatment. Among those
taking AEDs, 33 were on monotherapy, and 15 on polytherapy withTable 4
Number of abnormalities on the history, symptoms and signs, and on instrumental
investigations listed in Tables 1 and 2 among the 45 possible MID patients included.
Number of abnormalities NP
Three AT1 and 3 AT2 5
Three AT1 and 4 AT2 6
Three AT1 and 5 AT2 7
Three AT1 and 6 AT2 6
Three AT1 and >6 AT2 5
Four AT1 and 3 AT2 3
Four AT1 and 4 AT2 5
Four AT1 and 5 AT2 2
Four AT1 and >5 AT2 4
Five AT1 and 3 or more AT2 1
<3 AT1 but >10 AT2 1
NP, number of patients; AT1, abnormalities of Table 1; AT2, abnormalities of Table 2.two (n = 11) or three AEDs (n = 4). The AEDs most frequently used
in this study were levetiracetam (n = 21), lamotrigine (n = 20), and
valproic acid (n = 8). The AEDs most frequently applied in
monotherapy were lamotrigine, (n = 13), levetiracetam (n = 12),
and gabapentin (n = 4) (Table 3). The combination therapies most
frequently applied were valproic acid with levetiracetam (n = 3),
levetiracetam with oxcarbazepine (n = 2), and levetiracetam with
lamotrigine and lacosamide (n = 2). Among those receiving
levetiracetam 12 were on a monotherapy and nine on a
polytherapy with one or two other AEDs. The second most
frequently administered AED was lamotrigine. Thirteen patients
were on a monotherapy with lamotrigine and 7 took lamotrigine in
combination with another AED.
Twenty-ﬁve patients with mitochondrial epilepsy attended at
least one follow-up visit. In none of these patients epilepsy was
refractory. Outcome of the included patients was not systemati-
cally investigated in the present study, but among the 25 who
repeatedly attended the hospital, seizures were well controlled in
the majority of the cases, and only in single patients in whom
seizures recurred, the AED dosage had to be adopted or the AED
had to be replaced.
4. Discussion
The present study shows that epilepsy occurs in 14% of adult
patients with a deﬁnite, probable, or possible MID. The prevalence
of mitochondrial epilepsy was higher in deﬁnite and probable
MIDs than in possible MIDs. In 65% of the cases, epilepsy had a
structural and in 35% a genetic cause. Seizures were generalised in
85% of the cases, focal in 10%, and focal and generalised in 3%.
Eighty percent received an AED therapy but 18% were without AED
at the last visit or admission.
Only few studies have been carried out, which have systemati-
cally investigated epilepsy phenotypes in the context of MIDs.5–7 In
a study of 23 children with MID and epilepsy, 70% had refractory
epilepsy in association with progressive encephalopathy.5 Patients
with epilepsy were more likely to have complex-I defects than
children without epilepsy. Patients without epilepsy were more
likely to have a complex-III or complex-IV defect than patients
with epilepsy.5 In a study on 48 MID patients with epilepsy, 2 had
Ohtahara syndrome, 10 West-syndrome, 12 Lennox–Gastaut
syndrome, 2 Landau-Kleffner syndrome, 14 generalised epilepsy,
and 8 focal seizures.6 In a study on 56 children with MID and
epilepsy, 2 had a refractory neonatal status epilepticus, 21
myoclonic epilepsy, 8 infantile spasms, 21 refractory/recurrent
Fig. 2. Causes of structural/metabolic epilepsy among patients with a deﬁnite, probable, or possible MID.
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these cases, epilepsy was preceded by other phenotypic features of
the MID.7 In the latter study 60% of the patients had more than one
seizure type.7 One study investigating 22 children with deﬁnite,
probable, or possible MID showed that 17 participants had
generalised seizures and 5 partial seizures.8 Among the 17 patients
with generalised seizures, 4 started with focal seizures.8 It is not
clear why none of the cases included in the present study was
diagnosed with a speciﬁc electroclinical syndrome, myoclonic
seizures or epilepsia partialis continua, but these ﬁndings may be
explained by the fact that only adult patients were included in this
study and that the majority of patients described here had
probable and possible but not deﬁnite MIDs.
Concerning the frequency of epilepsy in patients with MIDs,
only limited data are available.5,9 Seizures have been reported to
occur in 25–71% of paediatric patients with biochemically
conﬁrmed MID5,9,10 but in small series of MIDs 100% of the
patients with AHS or MERRF-syndrome had developed epilep-
sy.10,11 Seizures were reported in about 40% of the patients with
Leigh-syndrome11 and are also a frequent feature of SCO2
mutations but are rare in SURF1 deﬁciency.12 In a study of 113
paediatric MID patients 44 (39%) had non-speciﬁc encephalopathy
and of these 50% had epilepsy.13 Contrary to these ﬁgures in
paediatric patients, the prevalence of epilepsy in adult MIDs was
only 14% in the present study. The discrepancy could be explained
by the poor genotype/phenotype correlation in MIDs, the fact that
the present study also included non-biochemically conﬁrmed
probable and possible MIDs, and the fact that the prevalence of
epilepsy depends on the type of MIDs included in a study. Epilepsy
is deﬁnitively more frequent in some MIDs than in others. In some
of the MIDs epilepsy even dominates the phenotype, such as in
MELAS-syndrome, MERRF-syndrome, Leigh-syndrome, MEMSA-
syndrome, MIRAS-syndrome, SANDO, pontocerebellar hypoplasia,
or AHS.14 AHS should be particularly suspected in cases with
fulminant onset focal epilepsy, epilepsia partialis continua, orstatus epilepticus and predominant occipital epileptiform dis-
charges.15 In the other syndromic MIDs, epilepsy occurs only
occasionally. The prevalence of epilepsy may be higher in studies,
which include MIDs that are frequently associated with epilepsy as
compared to MIDs with low prevalence of epilepsy. A further
reason could be the high phenotypic heterogeneity within a
syndrome, within a family or sibship, and between families. The
prevalence is also dependent on how thoroughly patients with
syncopes, collapses, falls, states of impaired consciousness, or
temporary behavioural, sensory or motor deﬁcits suggestive of a
seizure or epileptic state, are further investigated.
Though some of the AEDs given in the present study are
mitochondrion-toxic (in particular valproic acid, carbamazepine,
and oxcarbazepine),14 these AEDs were continued if seizure
control was acceptable, which was the case in most of these
patients, if severe and compromising side effects were absent or
tolerable, and if patients did not consent with a change of the AED.
However, patients were generally informed about the mitochon-
drion-toxicity of various AEDs (valproic acid, carbamazepine,
phenytoin, phenobarbital, oxcarbazepine) and alternatives to
these agents, which include lamotrigine, levetiracetam, gabapen-
tin, and lacosamide were proposed.14 Levetiracetam and lamo-
trigine may even exhibit a protective effect against mitochondrial
dysfunction.16 Beneﬁcial effects in addition to the antiepileptic
effect have been also reported for valproic acid, carbamazepine,
and lamotrigine (antidepressive effect) for pregabalin (anxiolytic
effect), and for gabapentin and pregabaline (antineuralgic effect),
which have been observed also in patients with MIDs [personal
communication]. None of the patients described in this study used
the ketogenic diet (high fat, adequate protein, low carbohydrates)
although this diet has been found to be particularly effective in
MIDs with myoclonic seizures, such as in Dravet syndrome17 and
in patients carrying mtDNA deletions.11 Vagal nerve stimulation
does not seem to be particularly effective in mitochondrial
epilepsy.5,18 Antioxidants have been proposed as adjunctive agents
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excess of free radicals.19
In conclusion, this study shows that mitochondrial epilepsy in
adults appears less frequently than previously believed but the
prevalence is strongly dependent on the selection of MID patients.
Mitochondrial epilepsy is most frequently associated with a
structural/metabolic cerebral lesion. In one-third of the cases,
cerebral imaging is normal. Generalised seizures are considerably
more frequent than focal seizures. AEDs recommended for the
treatment of mitochondrial epilepsy are levetiracetam, lamotri-
gine, gabapentin, and lacosamide. Outcome of MID patients with
epilepsy is favourable if mitochondrion-toxic AEDs are avoided.
Only if epilepsy is refractory to non-mitochondrion-toxic drags,
mitochondrion-toxic AEDs may be tried.
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